Arcosa, Inc. (ACA)
$
91.14
+1.27 (1.39%)
Key metrics
Financial statements
Free cash flow per share
5.1643
Market cap
4.4 Billion
Price to sales ratio
1.7090
Debt to equity
0.6870
Current ratio
1.9829
Income quality
5.3949
Average inventory
362.4 Million
ROE
0.0321
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Arcosa, Inc., along with its subsidiaries, specializes in providing infrastructure-related products and solutions targeting construction, energy, and transportation markets across North America. The company operates through three main segments: Construction Products, Engineered Structures, and Transportation Products. Within the Construction Products segment, Arcosa offers a range of natural and recycled aggregates, specialty materials, as well as trench shields and shoring products, catering to residential and non-residential construction, agriculture, and various infrastructure projects. The Engineered Structures segment supplies essential utility structures, wind towers, traffic and lighting structures, telecommunication structures, and storage tanks, playing a vital role in electricity transmission, wind power generation, and roadway projects. The Transportation Products segment provides inland barges and components such as fiberglass barge covers and winches, in addition to essential cast components for industrial and mining applications. Arcosa also manufactures axles and coupling devices vital for freight, tank, locomotive, and passenger rail transport. The company incurred an income tax expense of $36,300,000.00 indicating its tax obligations, while the gross profit stands at $515,200,000.00 highlighting the company's profitability from core operations. Additionally, the company incurred an interest expense of $70,900,000.00 reflecting its debt servicing obligations. The weighted average number of diluted shares outstanding is 48,800,000.00 reflecting potential dilution effects, and the company recorded a net income of $93,700,000.00 reflecting its profitability. The stock is reasonably priced at $89.34 appealing to a broad range of investors. However, it also has a low average trading volume of 260,831.00 indicating lower market activity. With a mid-range market capitalization of $4,449,099,354.00 the company is a steady performer in the infrastructure sector. Arcosa is a key player in the Industrial - Infrastructure Operations industry, contributing significantly to the overall market landscape. It belongs to the Industrials sector, driving innovation and growth, and its position enhances its relevance among investors seeking stability and potential returns.
Investing in Arcosa, Inc. (ACA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Arcosa, Inc. stock to fluctuate between $68.11 (low) and $113.43 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-25, Arcosa, Inc.'s market cap is $4,449,099,354, based on 48,816,100 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Arcosa, Inc. has a Lower Market-Cap, indicating a difference in performance.
Arcosa, Inc. pays dividends. The current dividend yield is 0.23%, with a payout of $0.05 per share.
To buy Arcosa, Inc. (ACA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACA. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Revenue: $2,569,900,000 | EPS: $1.92 | Growth: -41.28%.
Visit https://www.arcosa.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $113.43 (2024-11-25) | All-time low: $43.42 (2022-02-10).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Dallas, Texas, July 26, 2025 (GLOBE NEWSWIRE) -- Benefits Reimagined, a leader in AI-powered employee benefits platforms, proudly announces the launch of its innovative ACA application. This cutting-edge solution, built on the robust SAP Business Technology Platform (BTP), is designed to streamline compliance processes for organizations of all sizes.
zacks.com
Wind power surges as U.S. demand grows-stocks like DTE, BEP, ACA and D eye big gains amid tech-driven energy shifts.
businesswire.com
DALLAS--(BUSINESS WIRE)--Arcosa, Inc. (NYSE: ACA) (“Arcosa” or the “Company”), a provider of infrastructure-related products and solutions, today announced that it will release results for the second quarter ended June 30, 2025 after markets close on Thursday, August 7, 2025. The Company will host an earnings call to discuss the results at 8:30 a.m. Eastern Time on Friday, August 8, 2025. The call can be accessed as follows: Webcast and slide presentation: https://ir.arcosa.com The slides wil.
zacks.com
Arcosa (ACA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
Arcosa (ACA) could produce exceptional returns because of its solid growth attributes.
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Arcosa (ACA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
NEE, OGE, POR and ACA are capitalizing on soaring wind energy demand, with strong backlogs and expansion plans boosting growth.
zacks.com
Arcosa (ACA) is well positioned to outperform the market, as it exhibits above-average growth in financials.
zacks.com
ARCB, ACA and BAND have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2025.
wsj.com
The healthcare company also struck a deal with Novo Nordisk to sell Wegovy at a reduced price for cash-paying customers through its pharmacies.
See all news